AstraZeneca Receives the US FDA’s Orphan Drug Designation for its First Respiratory Biologic Fasenra (benralizumab) to Treat Eosinophilic Esophagitis

 AstraZeneca Receives the US FDA’s Orphan Drug Designation for its First Respiratory Biologic Fasenra (benralizumab) to Treat Eosinophilic Esophagitis

AstraZeneca Signs an Exclusive Option and Research Agreement with Transgene for Oncolytic Immunotherapies

Shots:

  • The US FDA has granted orphan drug designation to Fasenra (benralizumab) for the treatment of eosinophilic esophagitis (EoE) following OD designation for EGPA in Nov’2018 and for hypereosinophilic syndrome in Feb’2019             
  • The FDA’s OD designation is granted to the new therapies intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
  • Fasenra is a mAb targeting IL-5 receptor alpha on eosinophils, attracting NK cells to induce depletion of eosinophils via apoptosis and has received approval as an add-on maintenance treatment for severe, eosinophilic asthma in the US, EU, Japan

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Behance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post